Description
Recombinant monoclonal antibody to DR5. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the therapeutic antibody PRO95780 (Drozitumab). This reformatted human antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.
Target
DR5
Target Alias Names
CD262, death receptor 5, TRAIL receptor 2, TRAILR2, tumor necrosis factor receptor superfamily member 10B, TNFRSF10B, apomab
Isotype/Mimetic
IgM
Animal-Derived Biomaterials Used
No
Sequence Available
No
Original Discovery Methods
Naïve display libraries derived from human B cells, or naïve display libraries from animal B cells or Display libraries from synthetic or natural framework sequences
Original Discovery Information Provided On Datasheet
Yes
Antibody/Binder Origins
Animal-free discovery, Animal-dependent discovery (in vitro display, OR immunisation pre-2020), In vitro recombinant expression